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Abstract
Background Lung cancer is one of the most common types of cancer
worldwide, and it causes signiﬁcant challenges for patients due to
the poor survival rate and treatment-related side-eﬀects. Because of
lung cancer’s great burden, identiﬁcation and use of the patients’
preferences can help to improve patients’ quality of life.
Objective Interviews with patients who have lung cancer were used
to ascertain a range of experiences and to make recommendations
regarding the improvement of treatment based on these patients’
preferences. Because chemotherapy is the common treatment option
for lung cancer, we focused on this treatment. The interviews were
audio-taped, verbally transcribed and evaluated via content analysis.
Setting and Participants A total of 18 participants (11 men and
7 women) with small or non-small-cell lung cancer who were
receiving chemotherapy in one clinic were interviewed between June
and July 2013.
Results Two main aspects with diﬀerent subthemes were identiﬁed
during the interviews. One main aspect focused on organizational
context, such as the treatment day process, or experiences with dif-
ferent stakeholders, such as with the health insurance company or
physicians. The other category referred to experiences that inﬂu-
enced psychosocial factors, including physical and mental
experiences.
Discussion and Conclusion Patients reported diﬀerent experiences
concerning physical, psychological and organizational areas during
chemotherapy. Nevertheless, some potential areas for improving
care, and therefore the quality of life of patients with lung cancer,
could be identiﬁed. These improvement measures highlighted that
with small, non-time-consuming and inexpensive changes, the treat-
ment for patients with lung cancer can be improved.
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Introduction
Lung cancer is one of the most common cancers
with 1.8 million cases worldwide in 2012, and it
was the leading cause of cancer-related death.1
In relation to other cancers, lung cancer has a
poor 5-year survival rate. According to the dif-
ferent severities at diagnosis, the rate is between
2% for patients with distant metastases, 16%
for patients with cancer in the lung and nearby
lymph nodes and 49% for local lung cancer.2
Diﬀerent types of treatment for lung cancer
exist. Depending on the severity of the dis-
ease, surgery, chemotherapy or radiotherapy
are potential treatment options. Nevertheless,
chemotherapy is often undertaken either alone
or in addition to surgery. The treatment causes a
high burden for patients with cancer, including
physical complaints about the disease itself,
side-eﬀects of the therapy, mental stress, and a
lessening of family life and leisure activi-
ties. Other aﬀected areas include professional
limitations, ﬁnancial worries, the need to apply
for support services, the integration of inpatient
and outpatient therapy treatment measures, and
regular interaction with physicians and medi-
cal personnel.3
Corbin and Strauss pointed out that cancer
diseases require a high degree of services from
the private and medical setting of those
aﬀected.4,5 Recent studies show that physi-
cians often evaluate the needs and preferences
of their patients in a diﬀerent manner to the
patients themselves.6–8 Although the ramiﬁca-
tions of the patient’s perspective on their
disease are not a new discovery, it still has a
strong presence in recent studies. Most studies
focus on quantitative analyses and include the
use of a standardized questionnaire. For
example, M€uhlbacher et al. 9 used a discrete
choice experiment to ascertain patient prefer-
ences in relation to treatment of non-small-cell
lung cancer (NSCLC). They pointed out that
patients prefer an increase in ‘progression-free
survival’ and a reduction of ‘tumour-associated
symptoms’ (e.g. cough, pain). With these instru-
ments, it is diﬃcult to assess the broad range of
experiences and preferences that people have
had with their treatment or disease because only
some attributes can be evaluated. Furthermore,
a qualitative approach can give broader insight
and a more in-depth understanding of the expe-
riences and preferences with chemotherapy.
Qualitative studies of the burden and experi-
ences of cancer patients with chemotherapy also
exist but they mostly focus on cancer in general
and only some studies integrated patients with
lung cancer.10–13
Due to the great burden of the disease itself
and the eﬀects of the treatment, it is necessary to
assess patients’ treatment-related experiences to
help optimize their quality of life. Therefore, this
study focuses on the following two questions:
1. What is the particular burden for lung cancer
patients with regard to treatment?
2. Which recommendations for improving treat-
ment can be derived from the patients’
preferences?
Methods
We conducted semi-structured, guideline-based,
face-to-face interviews with patients suﬀering
from NSCLC or small-cell lung cancer. The
sample was recruited in cooperation with the
oncology outpatient day clinic at the Hannover
Medical School (MHH), Germany. The clinic
covers the whole spectrum of medical treatments
of a centre of supramaximal care with a total of
1518 beds and 452 783 patient contacts per year.
Patients were only included if they had under-
gone palliative chemotherapy at the time of the
study and had experienced at least one cycle of
chemotherapy. Patients who received adjuvant
chemotherapy were excluded. The study nurse,
who was not part of the treatment team, asked
those patients to participate in the interviews.
She provided information about the study’s aim,
the voluntary nature of consent, data collection
and data processing. A conﬁdential and anony-
mous handling of all personal data was
promised. All information about the study and
the declaration of consent was handed to the
patients. To record diﬀerent experiences, our
maximum variation sample included patients
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from various social backgrounds, ages and treat-
ment methods. Some patients were accompanied
by relatives during the interview. Owing to
ﬁnancial and time-related restrictions, the inter-
views were undertaken in the MHH’s rooms.
After written informed consent was obtained,
most patients were interviewed in the time lag
between the blood sample and chemotherapy in
the oncology outpatient day clinic. All inter-
views were conducted between June and July
2013. A total of 18 patients with lung cancer
were interviewed by a research assistant of the
Center for Health Economics Research Han-
nover. The number of interviews was not
predeﬁned. We stopped conducting interviews
after no new messages emerged. The study was
approved by the MHH’s Committee for Clini-
cal Ethics.
The interviews were structured using a guide-
line based on information from the literature,
which was developed in conjunction with an
interdisciplinary group of researchers. There-
fore, we conducted a systematic literature
review from 12 electronic databases (e.g.
EMBASE, MEDLINE), and included 20 quali-
tative and quantitative studies published
between 2000 and 2012. This guideline was
divided into four sections and contained open
questions that encouraged patients to talk
about their treatment-related experiences and
preferences in their own words. First, patients
were encouraged to describe an average treat-
ment day in hospital. Second, patients were
asked to talk about their expectations and
experiences concerning chemotherapy in
general, as well as the most harmful and bur-
densome side-eﬀects. These questions targeted
the experiences and eﬀects of the chemotherapy
on diﬀerent areas, including physical or mental
status, impact on daily living and contact with
other patients. Third, patients were also
encouraged to name ways of improving health-
care quality. The fourth section served as a way
of potentially addressing an important topic for
the patient. Additionally, some demographic
data (e.g. age, or smoking and working status)
were obtained before the interview. The inter-
views lasted 1–1.5 h and were audio-taped.
Each interview was completely verbally tran-
scribed and anonymized. As interviews were
conducted in German, the citations were trans-
lated by two professional translators who
are native speakers. Disparities were clari-
ﬁed bilaterally.
Data were analysed using qualitative con-
tent analysis methods with the additional
inclusion of inductive categories.14,15 To
ensure the accuracy of the analysis process,
two researchers (Kreis and Aumann) read the
interviews and paraphrased the relevant text
independently using the MAXQDA program.
A codebook was also generated. The
researchers analysed the text on the basis of
deductive categories, which were derived from
the questions in the guide. The inductive cat-
egories were developed directly from the text.
In addition, some sections of the interviews
were discussed by an interdisciplinary
research group to identify further induc-
tive categories.
To obtain an overall impression of the con-
tent, the transcripts were read and re-read. In
subsequent discussions, the researcher checked
the codes for consistency and agreement, and
resolved any diﬀerences by an iterative process.
The aim of a content analysis is to identify the
cross-relationships, repetitions, commonalities,
and diﬀerences of the statements to demonstrate
a trend regarding the results. To achieve this, all
interpretations and arguments are documented
and supported by citations.
Results
Participants
A total of 18 patients (11 men and 7 women)
with lung cancer completed the interviews. The
average ages were 75 years for the men and
63 years for the women. Three of the 18 patients
had a small-cell lung cancer diagnosis and 12
patients received additional radiation therapy.
All patients were at a higher disease stage
(>IIIA) due to their late diagnosis. Further
demographics and cancer status are described
in Table 1.
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Themes
During the content analysis of the interviews, we
identiﬁed four main themes. The ﬁrst theme
describes the chemotherapy-related experiences
and preferences of patients with lung cancer in
relation to the organizational aspects of their
treatment, especially the day they receive
chemotherapy. The second and third themes
focus on experiences with diﬀerent stakeholders
(physicians and the health insurance company)
and the last category contains treatment-related
experiences and preferences that inﬂuence psy-
chosocial factors, including physical and mental
experiences, and changes in the patient’s
social environment.
Theme 1: Experiences and preferences during the
treatment day
All patients described a very similar course of
treatment, which is characterized by the collec-
tion of a blood sample, a consultation with the
physician to discuss the blood values and to
determine the next treatment steps, the collec-
tion of the chemotherapy substance at the
pharmacy, and the subsequent chemotherapy.
This treatment procedure was described by
patients in a clear and factual language without
many breaks. For some patients, it is an ordi-
nary day of treatment due to the large number
of therapy cycles and it is described as a natural
process. Regarding the treatment day, some
Table 1 Participant socio-
demographics and clinical setting
Number
Age,
Gender Diagnosis Stages Radiation Chemotherapy
1 75m non-small IV yes Second-line therapy,
9 cycles; intravenous
2 68m Small IV no Second-line therapy,
2 cycles; intravenous
3 61f non-small IV yes Third-line therapy, oral
4 63m non-small IV yes Second-line therapy,
2 cycles, intravenous
5 48f non-small IV yes First-line therapy, oral
6 74m non-small IV no First-line therapy, oral
7 59f non-small IV yes First-line therapy,
10 cycles; intravenous
8 70f non-small IV yes First-line therapy, oral
9 69m non-small IV no Fourth-line therapy,
2 cycles; intravenous
10 65m Small IV no First-line therapy,
1 cycle; intravenous
11 76f non-small IIIA no First-line therapy,
2 cycles; intravenous
12 65m non-small IV yes Second-line therapy,
2 cycles; intravenous
13 60m non-small IIIB yes Third-line therapy,
2 cycles; intravenous
14 72m non-small IV yes Third-line therapy,
7 cycles; intravenous
15 61f non-small IV yes Fifth-line therapy, oral
16 70m non-small IV yes Second-line therapy,
97 cycles; intravenous,
maintenance therapy
17 75m small IIIB yes Second-line therapy,
2 cycles; intravenous
18 67f non-small IV no Second-line therapy, oral
f = female, m = male.
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patients also reported long waiting times, partic-
ularly between individual treatment steps.
[. . .] and then, normally, a blood sample is ﬁrst
taken, two ampoules, and it is sent to the labora-
tory, then comes an appointment with the
physician, in which the lab results are discussed
once again, and he decides whether or not chemo
will be performed, you understand? And yes, then
comes another waiting period. One has to come
down here and register, then wait, then the phar-
macy delivers the chemo mixture and that can take
a while and, oh well. (P9, 69m)
Nevertheless, the burden of waiting times was
perceived diﬀerently among the patients. Those
who had a long distance to travel to the hospital
perceived the waiting time as a large burden
because the driver had to allow time for the treat-
ment and journey. This also limited the patients’
ﬂexibility and freedom, and ensured that the
patients were dependent on others. Most patients
mentioned the waiting times but accepted them
and considered them to be unimportant, irrele-
vant, or a small problem compared to other
problems. Thus, they approved of the waiting
times and thought it impossible to accelerate
individual treatment sections.
Yes, but what the heck, because I think that [the
waiting period] is all stuﬀ that takes a back seat. In
that respect, they can’t possibly please everybody.
(P4, 63m)
However, the patients did make suggestions
for design improvements regarding the waiting
times. First, patients wished for greater privacy
during chemotherapy, such as through the provi-
sion of more treatment rooms, smaller rooms, or
the inclusion of extra curtains. Second, patients
requested more rooms so that no patient has to
wait in the corridor before starting chemother-
apy. Third, some patients wanted beds, or more
rooms or comfortable chairs, while another
patient would welcome the provision of
headphones and music during chemotherapy.
All these suggestions indicate that patients want
to feel comfortable and need privacy.
Perhaps they should [. . .] hand out earphones for
music or something like that, don’t you think?
Then it wouldn’t be so monotonous, one would
get drowsy at the same time and doze a little, but
with a little music in your ears, that’s not a bad
idea, is it? (P15, 61f)
Theme 2: Experiences with physicians:
As patients spend much time waiting for
chemotherapy, meaning a highly stressful situa-
tion, they wanted to feel comfortable.
I do not know [. . .], but you are nervous and you
also have fears, isn0t it so? The clinic should be a
place where you get the help to ignore the medical
stuﬀ and to relax. (P15, 61f)
Therefore, the organizational conditions, such
as those mentioned above, and the personal rela-
tionship with the staﬀ members, especially the
physicians, must be suitable. Overall, the inter-
viewed patients were very satisﬁed with the
physicians. They trusted their physician regard-
ing treatment decisions and felt unable to
request improvements regarding the therapies.
[. . .] the doctor already has to know how to
improve that [the therapy]. (P11, 76f)
However, during the interviews, some patients
expressed thoughts on improvements regarding
the contact and communication with physicians.
Patients wished for a certain level of continuity
with the physicians and a frequent change of
physicians was criticized because the patients
had to build up conﬁdence again.
What I still regret is that one has just built up a
rapport with a physician and he disappears over-
night. (P2, 68m)
Chemotherapy is a tense situation. Routine
and trust in physicians can help the patients to
cope better with this situation. Patients often
only knew the name of the senior physician,
because other physicians frequently changed.
Therefore, the conﬁdence base of the patients
that was given referred exclusively to the senior
physicians. Patients know about the diﬃculties
for a hospital to structure a treatment plan so
that everybody always has the same contact per-
son, but at least they wanted to be informed by
the senior physician or another known staﬀ
member about any changes in the treatment
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responsibility. Nevertheless, the frequency of
physician changes should be kept to a minimum.
For patients who have regular contact with
one physician, conversations are important to
build up trust and reduce fears. Some patients
mentioned that the physician took substantial
time with them and created a very personal
atmosphere during conversations.
Well, as far as the physicians are concerned, they
have a lot to do, they are really overworked, aren’t
they? But I must say that I am impressed with the
physicians here. They have really taken their time
and put in a lot of eﬀort. Recently, I had an
appointment with Dr. A, shortly before he left the
clinic. He devoted more than an hour to me.
Which physician allows more than one hour for a
patient? (P3, 61f)
This personal atmosphere is an important pre-
requisite when it comes to the provision of
information and its content. As patients are
often overwhelmed by the range of information
available from the internet, friends, and family,
they need the help of a health-care professional
like a physician to select correct and impor-
tant information.
It was shown that patients generally feel well-
informed by the physician about the treatment.
Some patients, however, wanted more informa-
tion about the handling and treatment of
side-eﬀects to acquire more security in dealing
with disease speciﬁc situations. In particular,
they were interested in whether the doctor was
the right contact for the diﬀerent side-eﬀects and
what therapies are available to combat them.
With regard to the dermatological history, one
should really know from the very beginning, who
to turn to if eczema or something else really
appears. (P18, 67f)
Likewise, regarding types of communication,
patients had diﬀerent desires. One patient did
not wish to receive information via telephone.
This patient feared a dispensation of personal
contact and the possibility to talk about
potential problems face-to-face. However, other
patients preferred shorter methods of communi-
cation, because they had already experienced a
long journey from their homes to the hospital
and the side-eﬀects of the chemotherapy cause
high physical strain.
I called today and said: Yes, the radiotherapy
comes to an end tomorrow. What happens now?
Should I have another CT and where? Here or
there? What do I need to take with me? I was told:
‘Yes, on Thursday – the day after tomorrow – here
at the clinic. Then we can discuss it’. But that came
from the oﬃce, not from the physician. Now, I ask
myself, is that absolutely necessary. Because there
are no facts available, absolutely nothing. If I
came here and some tests had been done or a CT
had meanwhile delivered a result, and they had
wanted to discuss that with me face to face, then
okay. I don’t really think one wants to do that on
the phone. But only so that you will probably be
told: ‘Yes, see to it that you get a referral for a CT
from your GP and get the necessary blood tests for
the CT done. And as soon as you have the results,
come and see me again’. That would have been
more logical in my opinion. (P1, 75m)
Altogether, this section shows that, besides
organizational aspects, physicians also play an
important role in giving patients a trustful atmo-
sphere during chemotherapy and to make them
feel comfortable. Therefore, they need a continu-
ous contact person who is informed about the
disease and treatment. Furthermore, new physi-
cians should be introduced to the patients by the
contact persons. The physician could improve
the conﬁdence by taking enough time for treat-
ment discussions, asking patients how they want
to get information, and to concentrate more on
the patients0 individual needs and personality.
This could create enough transparency to
increase the acceptance of the organizational
structure, such as waiting times, and reduce the
patients’ fears.
Theme 3: Experiences with health insurance
In terms of the organizational context, patients
often had experiences with other stakeholders,
especially regarding health insurance. For
patients with lung cancer in particular, the
absorption of travel costs was of great impor-
tance. As patients are not allowed to drive or
they feel unable to drive to the therapy them-
selves, they need a taxi or a relative to drive
them. Due to most patients being unable to
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work, paying for a taxi is an additional ﬁnancial
burden. Because of this, patients can apply for
reimbursement of taxi rides to the chemotherapy
sessions using their health insurance. The inter-
views showed that most communication and
settlement between the health insurance com-
pany and patients is simple and straightforward.
In many cases, patients were supported by the
applications made by hospital employees or
physicians. Nevertheless, sometimes there were
coordination problems with the health insurance
companies, which were perceived as particularly
troublesome by the patients. One patient
reported that taxi rides for computer tomogra-
phy (CT) were not approved as they were not
part of the chemotherapy, and the patient would
not ‘beg for a beneﬁt’.
The taxi fares to chemo were covered, but those to
CT, for example, were not, so I had to ask my girl-
friend if she would drive me because I can’t aﬀord
a taxi. Who can aﬀord a taxi there and back? Hey?
And if we have to come to the clinic twice a week,
without receiving chemo or radiotherapy, who
pays for that? (P3, 61f)
Equally, another patient was not compensated
for the rides because of a treatment option avail-
able in another hospital, which was closer to the
patient’s home but not a certiﬁed centre.
Another patient reported that the health insur-
ance company had verbally conﬁrmed they
would ﬁnance the services, but subsequently
refused until a new request was made. One
patient reported problems completing the appli-
cations because she did not know whether the
disease was chronic. As a result, she accidentally
made false statements, consequently had to
ﬁle an objection, and incurred considerable
expenses. In addition, the long waiting time for
the granting of support services through health
insurance was criticized. Altogether, the patients
who have had bad experiences with health insur-
ance feel overwhelmed with the administrative
burden because they never had in such an extend
contact to the health insurance before, and so
this situation is new for them. Without help
from nurses and physicians, the situation for
the patients would further deteriorate and,
therefore, they wish to have support from the
health insurance.
Theme 4: Treatment-related experiences and
preferences of the patients that influence
psychosocial factors
Besides the experiences with the organizational
factors and stakeholders, the chemotherapy had
an inﬂuence on the patients’ psychosocial situa-
tion. The patients reported many physical
side-eﬀects, such as general sickness, low load
capacity, and absence of appetite due to the
chemotherapy. Problems with changes in their
external appearance because of hair loss or skin
rashes were also mentioned.
These side-eﬀects caused great physical limita-
tions resulting in lower performance levels and
ﬂexibility. As a result, patients reported a
decrease in sporting and household activities.
Additionally, patients often were unable to con-
tinue with their work. This situation occurred
very suddenly and, thus, changed the patients’
daily routines. Combined with their inability
to work, some patients were worried about
their ﬁnancial security and economic existence,
especially self-employed patients. Some of them
even had to apply for early retirement due to
their illness.
Well, let me say this: I have been written oﬀ work
and I suddenly have to spend the whole day at
home. I have been ripped out of my environment,
my professional life. (P5, 48f)
Whether someone can aﬀord it is an issue that
relates to the economic situation, or if it is some-
one who is on the dole who gets cancer. That is
actually another (unclear) aspect of this illness,
that one is drained ﬁnancially. So, if it causes us to
lose our company now, which we feared at the
beginning, that would be a disaster. (P4, 63m)
The changes in their daily life along with the
fears resulting from the disease and the treat-
ment cause psychological eﬀects.
Yes, I’m at the end of my strength. I can hardly
move, can hardly walk, can hardly breathe. If I
didn’t have my girlfriend, I wouldn’t be able to do
anything, hey? (P3, 61f)
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The psychological eﬀects are characterized by
diﬀerent feelings. Patients diﬀer between hopes
and fears. On the one hand, the patients wish
that the chemotherapy helped and extended
their life but, on the other hand, they are afraid
of physical disabilities, a lack of ﬂexibility, and
loss of independence. Due to these psychological
strains, patients develop various strategies to
deal with these limitations.
One group of patients took every opportunity
to go for a walk and undertook speciﬁc breath-
ing exercises. These patients wanted to actively
take part in life and keep in touch with family
and friends.
I try to increase right now my walking distance so
that I go out and walk around (P7, 59f)
Another group of patients stayed at home and
cut themselves oﬀ from their external environ-
ment. These patients often reported changes in
mood and that they sometimes behaved defen-
sively and aggressively.
It isn0t interesting anymore. I watch no news. It is
all the same to me whatever happens anywhere in
the world (P4, 63m)
Despite these diﬀerences between the two
groups of patients, family is an important factor
for both. They need support from the family to
deal with the disease but they do not want to be
a burden to their family. Nevertheless, patients
report positively about the family growing closer
together and building a better relationship,
although the family was shocked about the diag-
nosis and it is diﬃcult for them to deal with
the situation.
The family recognized if somebody does not feel
well, then you must stick together. (P5, 48f)
There were, however, quite contradictory
experiences concerning the circle of friends.
Some patients distanced themselves from their
friends and in some cases lied to them in order
to avoid talking about their real problems.
Well, the behaviour of friends that you spend time
with is of course always a little/they said it again
today, everyone always says ‘Oh, you’re looking
good!’ And then I think to myself: ‘Oh! I don’t
want to hear that word again!’ Because it’s always
such a poor little cancer patient, as though all of
them walk around with bald heads or wigs, which
constantly remind everyone of the situation. So
one is/I am never free of the situation in that sense.
(P18, 67f)
However, for patients without a family, their
circle of friends was of great importance, provid-
ing household support or rides to hospital. For
these patients, friends were indispensable. Alto-
gether, chemotherapy leads to high physical and
psychological strain for the patients. Strategies
for dealing with these problems diﬀer between
the patient groups. Nevertheless, contact and
support from family plays an important role
for patients.
Discussion
Patients with lung cancer have had a variety of
experiences that have aﬀected their physical,
psychological, and organizational areas of life.
During the interviews, the patients with lung
cancer sometimes directly reported their prefer-
ences to support and improve treatment. In
addition, based on the patient-reported experi-
ences, further recommendations can be derived.
This section focuses on improvements to the
treatment of patients with lung cancer, and dis-
tinguishes between patients’ reported wishes and
recommendations based on their reported expe-
riences, in which some criteria mutually
inﬂuenced each other. In other words, an
improvement in organizational factors could,
for example, enhance mental factors too.
First, some patients complained about long
waiting times during chemotherapy and desired
a more acceptable design of waiting times. This
included greater privacy, such as through extra
curtains or smaller treatment rooms. Other stud-
ies also identiﬁed the waiting time as an
important aspect,10,16,17 because patients get
frustrated, angry, and irritated. Mitchell et al.’s
results show that patients think that the ‘delay in
the clinic might be caused by adverse events,
staﬀ shortages and the general pressure of the
throughput of patients’.10 Conversely, in our
study, patients expressed the opinion that the
waiting time could not be reduced but, instead,
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better shaped. Nevertheless, it could be an
option to reduce the waiting time during
chemotherapy by the family doctor taking a
blood sample 1 day earlier so that the patients
start the treatment day by directly discussing the
treatment plan with the physician in the clinic.
As the waiting time would be reduced, this could
also improve the situation for the accompany-
ing person.
Second, some patients reported problems
communicating with their health insurance
company concerning travel costs. Therefore
the health insurance should optimize their
quality and time of advice for these patient
groups. Another option is to use and inte-
grated these problems into the existing
structure in the clinics. Although patients have
the support of the physicians and nurses, this
is not always suﬃcient. The capacity for so-
called case managers, which are often located
at the clinic, should be increased so that they
have more time to go through the application
documents together with the patients. How-
ever, a systematic review of the use of such
measures to optimize cancer care pathways
shows that case management is a black box,
and it is not clear which areas contribute to
an improvement of the pathways, due to dif-
ferent or unclear deﬁnitions.18 Therefore, the
case manager could have a gatekeeper function
to optimize the treatment’s structure, or the
function of an advocate to answer labour and
social law questions. It is also possible for the
health insurance company to provide addi-
tional consultancy services that are specialized
in treatment-related problems for patients with
cancer using health insurance.
Third, the interviews showed the patients’
general satisfaction with their physicians.
Leydon et al. 19 conﬁrmed this relationship of
trust by patients with cancer. Frequently chang-
ing physicians in the clinic was perceived
negatively by patients, and a German study
reached the same conclusion.20 To improve the
patients’ understanding of this situation, physi-
cians should look for an open and honest
conversation with patients and should respect
their personality.
Fourth, patients with lung cancer reported
diﬀerent preferences regarding forms of commu-
nication. Some patients preferred personal
contact with the physicians, while others
favoured communication via telephone. In par-
ticular, those patients with a long distance to
travel wanted to receive information via tele-
phone. Thus, to communicate with patients in
their preferred way, physicians should ask their
patients at the beginning of the therapy which
method of communication they want to use.
In addition, patients required more information
about the treatment of side-eﬀects. Comprehen-
sive information about the chemotherapy itself
existed, but there was a lack of clear treatment
options for possible side-eﬀects. Clinic staﬀ
should advise who the appropriate contact part-
ners are for the patients. A further possibility
would be to integrate patients into an interdisci-
plinary ‘tumour board’. The National Cancer
Institute deﬁned a tumour board as a ‘treatment
planning approach in which a number of doctors
who are experts in diﬀerent specialties (disciplines)
review and discuss the medical condition and
treatment options of a patient.21 This includes
medical, surgical and radiation oncologists.
Within such a meeting, patients could be truth-
fully informed about side-eﬀects and treatment
options by specialists. Better treatment of side-
eﬀects could also positively inﬂuence patients’
abilities to participate in work and social life. This
tumour board should be convened during the pro-
cess of therapy decisions, as well as in the course
of individual treatment steps, as patient-reported
experiences might be relevant for the subsequent
treatment steps.
Fifth, another fear that patients had was the
ﬁnancial burden, not only because of the inabil-
ity to work, but also due to the indirect costs,
for example those caused by searching for a
driver to the clinic. This form of stress was
associated with a high psychological burden for
patients and their family. Timmons et al. 22 also
conﬁrm these results in a qualitative analysis of
patients with breast, lung and prostate cancer.
Thus, greater support in the household and
subsidies for taxi expense could lessen
this burden.
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Limitations
Some study limitations need to be acknowl-
edged. This study was conducted in one large
clinic with a centre of supramaximal care, which
limits the transferability of the organizational
ﬁndings to other, especially smaller, clinics.
Nevertheless, the organizational process of
chemotherapy is largely standardized, particu-
larly in centres with certiﬁcation, which means
that the organizational aspects may not be dif-
ferent in other clinics. Furthermore, some
patients had prior experiences with other clinics.
As this study only included patients from the
German health-care system, the transferability
of the experiences with the health insurances is
limited. Additionally, the interviews were con-
ducted in the rooms of the oncology outpatient
day clinic. Patients may have answered questions
incompletely or dishonestly. However, as the
interviewer was not a member of the clinic, she
may have been more likely to create an atmo-
sphere of trust compared to a clinic member.
Finally, a selection bias may have aﬀected the
results because we could not interview patients
whose state of health did not allow study partici-
pation. This group of patients could have had
other treatment-related experiences and diﬀerent
preferences for chemotherapy.
Conclusion
This study analysed the burden for patients with
lung cancer caused by the treatment. Compared
to other studies, we identiﬁed relevant experi-
ences that inﬂuenced the atmosphere and well-
being of patients with lung cancer during
chemotherapy. Therefore, we identiﬁed that the
experiences with organizational processes,
health insurance, physicians, and physical and
psychological side-eﬀects inﬂuenced the patients’
preferences. Furthermore, we used the identiﬁed
experiences and preferences to derive recommen-
dations about how the treatment can be
modiﬁed. Based on their experiences, the follow-
ing potential areas for improvement were
deﬁned: changing the waiting times, providing
more information about the side-eﬀects of the
treatment options, making individual arrange-
ments regarding communication methods
between the physician and patient and improv-
ing information about the changing physicians
during treatment. With these changes, patients
could feel better during chemotherapy and have
fewer fears so that their quality of life could
be improved. They are also more likely to
accept organizational limitations, such as
waiting times.
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